Last reviewed · How we verify
Active Comparator: Aspirin+Clopidogrel
Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent thrombotic events.
Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent thrombotic events. Used for Acute coronary syndrome, Secondary prevention after myocardial infarction, Stroke prevention in patients with recent ischemic stroke or transient ischemic attack.
At a glance
| Generic name | Active Comparator: Aspirin+Clopidogrel |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Drug class | Dual antiplatelet agent |
| Target | COX-1 (aspirin); P2Y12 receptor (clopidogrel) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Clopidogrel is a P2Y12 adenosine diphosphate receptor antagonist that prevents platelet aggregation. Combined, they provide dual antiplatelet therapy with complementary mechanisms to reduce clot formation.
Approved indications
- Acute coronary syndrome
- Secondary prevention after myocardial infarction
- Stroke prevention in patients with recent ischemic stroke or transient ischemic attack
- Prevention of stent thrombosis after percutaneous coronary intervention
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Dyspepsia
- Intracranial hemorrhage
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
- Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND (PHASE4)
- Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke (PHASE3)
- GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation (PHASE3)
- Prospective Registry of Elderly ESUS With PFO
- Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure (PHASE2, PHASE3)
- Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: